Search research articles
Contact Us
Filters
Showing results (1-10 of 140) with videos related to
Page
of 14
Sort By:
Cancer Biology & Therapy
|
June 12, 2014
Prolonged low intensity EPOCH-rituximab has improved toxicity in Burkitt lymphoma compared with standard short, high intensity therapy
Shandiz Shahbazi, Cody J Peer, William D Figg
Cancer Biology & Therapy
|
May 6, 2017
Diagnosis, staging, and risk stratification in prostate cancer: Utilizing diagnostic tools to avoid unnecessary therapies and side effects
Louis Rodgers, Cody J Peer, William D Figg
Cancer Biology & Therapy
|
January 29, 2011
CHIP and gp78-mediated ubiquitination of CYP3A4: Implications for the pharmacology of anticancer agents
Cody J Peer, Tristan M Sissung, William D Figg
Cancer Biology & Therapy
|
August 7, 2013
Uncovering the genetic landscape driving castration-resistant prostate cancer
Timothy J Martin, Cody J Peer, William D Figg
Cancer Biology & Therapy
|
May 18, 2018
Tissue preservation with mass spectroscopic analysis: Implications for cancer diagnostics
O Morgan Hall, Cody J Peer, William D Figg
Cancer Biology & Therapy
|
October 11, 2021
Ibrutinib's off-target mechanism: cause for dose optimization
Sara M Zimmerman, Cody J Peer, William D Figg
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 12, 2017
Jumping the Barrier: Modeling Drug Penetration across the Blood-Brain Barrier
Cody J Peer, Cindy H Chau, William D Figg
Cancer Biology & Therapy
|
March 11, 2015
Targeted PI3Kδ inhibition by the small molecule idelalisib as a novel therapy in indolent non-Hodgkin lymphoma
Tracy C Okoli, Cody J Peer, Kieron Dunleavy, et al.
Pharmacogenomics
|
November 8, 2016
Pharmacogenomics and histone deacetylase inhibitors
Andrew Kl Goey, Tristan M Sissung, Cody J Peer, et al.
Seminars in Oncology
|
October 25, 2023
PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics
Yi Zeng, Oluwatobi Arisa, Cody J Peer, et al.
Page
of 14
Search research articles
Search
Showing results (1-10 of 140) with videos related to
Sort By:
Page
of 14
Cancer Biology & Therapy
|
June 12, 2014
Prolonged low intensity EPOCH-rituximab has improved toxicity in Burkitt lymphoma compared with standard short, high intensity therapy
Shandiz Shahbazi, Cody J Peer, William D Figg
Cancer Biology & Therapy
|
May 6, 2017
Diagnosis, staging, and risk stratification in prostate cancer: Utilizing diagnostic tools to avoid unnecessary therapies and side effects
Louis Rodgers, Cody J Peer, William D Figg
Cancer Biology & Therapy
|
January 29, 2011
CHIP and gp78-mediated ubiquitination of CYP3A4: Implications for the pharmacology of anticancer agents
Cody J Peer, Tristan M Sissung, William D Figg
Cancer Biology & Therapy
|
August 7, 2013
Uncovering the genetic landscape driving castration-resistant prostate cancer
Timothy J Martin, Cody J Peer, William D Figg
Cancer Biology & Therapy
|
May 18, 2018
Tissue preservation with mass spectroscopic analysis: Implications for cancer diagnostics
O Morgan Hall, Cody J Peer, William D Figg
Cancer Biology & Therapy
|
October 11, 2021
Ibrutinib's off-target mechanism: cause for dose optimization
Sara M Zimmerman, Cody J Peer, William D Figg
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 12, 2017
Jumping the Barrier: Modeling Drug Penetration across the Blood-Brain Barrier
Cody J Peer, Cindy H Chau, William D Figg
Cancer Biology & Therapy
|
March 11, 2015
Targeted PI3Kδ inhibition by the small molecule idelalisib as a novel therapy in indolent non-Hodgkin lymphoma
Tracy C Okoli, Cody J Peer, Kieron Dunleavy, et al.
Pharmacogenomics
|
November 8, 2016
Pharmacogenomics and histone deacetylase inhibitors
Andrew Kl Goey, Tristan M Sissung, Cody J Peer, et al.
Seminars in Oncology
|
October 25, 2023
PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics
Yi Zeng, Oluwatobi Arisa, Cody J Peer, et al.
Page
of 14